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Abstract 
Background: Prognostic biomarkers for cancer have the power to change the course of disease if they add 
value beyond known prognostic factors, if they can help shape treatment protocols, and if they are reliable. 
The aim of this study was to identify such biomarkers for colon cancer and to understand the molecular 
mechanisms leading to prognostic stratifications based on these biomarkers.  
Methods and Findings: We used an in house R based script (SSAT) for the in silico discovery of 
stage-independent prognostic biomarkers using two cohorts, GSE17536 and GSE17537, that include 177 and 
55 colon cancer patients, respectively. This identified 2 genes, ULBP2 and SEMA5A, which when used jointly, 
could distinguish patients with distinct prognosis. We validated our findings using a third cohort of 48 patients 
ex vivo. We find that in all cohorts, a combined ULBP2/SEMA5A classification (SU-GIB) can stratify distinct 
prognostic sub-groups with hazard ratios that range from 2.4 to 4.5 (p≤0.01) when overall- or cancer-specific 
survival is used as an end-measure, independent of confounding prognostic parameters. In addition, our 
preliminary analyses suggest SU-GIB is comparable to Oncotype DX colon(®) in predicting recurrence in two 
different cohorts (HR: 1.5-2; p≤0.02). SU-GIB has potential as a companion diagnostic for several drugs 
including the PI3K/mTOR inhibitor BEZ235, which are suitable for the treatment of patients within the bad 
prognosis group. We show that tumors from patients with worse prognosis have low EGFR 
autophosphorylation rates, but high caspase 7 activity, and show upregulation of pro-inflammatory cytokines 
that relate to a relatively mesenchymal phenotype.  
Conclusions: We describe two novel genes that can be used to prognosticate colon cancer and suggest 
approaches by which such tumors can be treated. We also describe molecular characteristics of tumors 
stratified by the SU-GIB signature. 
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Introduction 
Foreseeing the prognosis of colon cancer 
patients, especially those with stage II or III disease is 
critical as it will change treatment decisions. In 
addition to known prognostic factors, such as stage, 
mismatch repair proficiency, Kras and Braf mutation 
status, various prognostic assays based on molecular 
signatures have been developed as clinical tests (e.g. 
Oncotype DX colon, ColoPrint). A recent report that 
evaluated most oncological prognostic tests, including 








deficiencies in discovery and validation studies [1]. 
These include the lack of complete multivariate 
analyses where all prognostic factors are considered, 
lack of an evaluation of all survival measures, 
including overall survival, disease-free survival and 
response to therapy, and lack of validation in multiple 
cohorts. These criteria, as well as the possibility of 
using the test “in house” at minimum cost are 
considered essential in expediting the utilization of a 
molecular test in the clinic. We planned this study 
aiming to address most of these issues utilizing an in 
silico approach to identify a minimum number of 
prognostic genes and performed ex vivo as well as in 
silico validation studies with multiple cohorts. Our 
results suggest that the joint evaluation mRNA 
expression of two novel genes, ULBP2 and SEMA5A 
in colon cancer tumor tissue can identify patients with 
good, intermediate and bad prognosis, independent 
of stage, K-ras/B-raf mutation, and mismatch repair 
status. As prognostic signatures are considered 
valuable especially if they can predict response to 
therapy, we searched for therapeutic agents that 
would be suitable for the treatment of those patients 
with a predicted bad prognosis. Our results indicate 
that the PI3K/mTOR inhibitor NVP-BEZ235 is such a 
drug. At a molecular level, we find that tumors from 
patients with bad prognosis have decreased 
EGFR-Y1068 phosphorylation and increased Caspase 
7 cleavage, together with up-regulation of 
inflammatory cytokines; in line with our findings 
showing such tumors are more mesenchymal, as 
opposed to epithelial in character. 
Methods 
Study cohorts 
Patient characteristics of the 4 cohorts used in 
this study are summarized in Table S1 and Table S2. 
Datasets with gene expression data from 177 and 55 
tumor tissues (GSE17536 and GSE17537) were used as 
discovery cohorts [2]. Median survival times for 
patients within the GSE17536 and -37 cohorts were 
42.2 (0.9-142.6) and 41.7 (0.4-70.5) months 
respectively. For ex vivo validation of biomarkers of 
overall survival (OS) we used tumor tissues obtained 
from a third cohort (Ankara) consisting of 46 patients 
with a pathological diagnosis of colon cancer, 
collected at the Department of Gastroenterological 
Surgery, Yuksek Ihtisas Training and Research 
Hospital, Ankara, Turkey, following informed 
consent obtained from all patients. Information 
regarding overall survival time, follow-up status, age, 
gender, TNM stage, grade, perineural invasion and 
vascular invasion were available for all patients. 
Representative images from tumor sections are shown 
in Figure S1. Follow up times ranged from 1 to 49 
months. Median survival was 23 months for this 
cohort, as most patients had stage III disease. For 
genes that associated with OS, association with 
disease-free survival (DFS) was assessed in silico using 
the aforementioned datasets in addition to a third: 
GSE39582, which included data from 566 patients [3].  
In silico methods 
Microarray data analysis 
Gene expression data of tumor datasets were 
downloaded from GEO (http://www.ncbi.nlm.nih. 
gov/geo) and GC-RMA normalized without baseline 
transformation using GeneSpring v12.0. Clinical data 
related to these were downloaded from ArrayExpress 
(http://www.ebi.ac.uk/arrayexpress). For cell line 
gene expression analysis GSE36133 (Cancer Cell Line 
Encyclpedia) [4] and E-MTAB-783 (Cancer Genome 
Project) [5] datasets were downloaded from 
ArrayExpress and RMA normalized using 
GeneSpring v12.0.  
Semisupervised survival analysis tool (SSAT) 
This analysis aims the identification of probesets 
that can stratify patients into 2 groups with 
significantly different survival times as assessed by 
the log-rank test when a cut-off value of either 2, 4, 6, 
8, 10, 12 or 14 (log2 expression data) is used. Thus, 7 
different log-rank tests were performed for each 
probeset using an R (Bioconductor) based script. For a 
given probeset, the cut-off value with the lowest p 
value was used for further analyses. For GSE17536, 
SSAT could identify 24 of 48 genes that were 
previously validated as prognostic biomarkers for 
colon cancer [6]. Among significant genes, those that 
gave hazard ratios (HR) in opposite direction between 
two analyses (GSE17536 and GSE17527) were 0%, 5%, 
and 12.5% for the first 10, 20, and 40 most significant 
genes, respectively. 
Oncotype Dx colon risk group assignment 
Recurrence risk was calculated based on the 
expression of 7 test and 5 control genes, and each 
sample assigned to either a low or high risk group as 
previously described [3]  
Microarray based microsatellite instability 
determination 
Affymetrix probesets corresponding to a 
genomic signature that identifies colorectal cancer 
patients with MSI [7] available in the HGU 133A 
platform were identified. The median expression 
values of these probesets were calculated for samples 
within the GSE41258 human colon cancer dataset for 
MSI-high or -low, versus MSS subgroups, as the MSI 




status of samples in this dataset are known. These 
median values were then used as reference centroids 
for the classification of samples in GSE26682 (HGU133 
Plus 2.0) and GSE17536 (HGU133A) datasets. A 
correlation based classification was performed using 
the reference median values (MSI and MSS median 
values of 46 probesets) and the expression values for 
each test sample. The difference between MSI and 
MSS correlation values were used to generate a MSI 
index value for each sample. A threshold index value 
(0.45) that gave the maximum accuracy in both 
platforms was determined based on a ROC analysis. 
Samples with index values above 0.45 were classified 
as MSI, or MSS if the value was equal or below this 
threshold. 
TCGA based expression and proteomic analyses 
Level 3 RNA seq. and level 3 proteome data for 
132 colon cancer primary tumor tissues were 
downloaded from cancergenome.nih.gov via the 
TCGA data portal. Tumors were classified according 
to the SU-GIB signature using median gene 
expression values as thresholds for both ULBP2 and 
SEMA5A, yielding 37, 55 and 40 samples with good 
(G), intermediate (I) and bad (B) prognosis, 
respectively. ANOVA test was used to identify 
proteins with significantly different expression 
between groups, based on the RPPA data. ANOVA 
based differences in expression of inflammatory 
cytokines were identified using level 3 RNA-seq. data 
of TCGA.  
RT-PCR 
Total RNA was extracted from either 
snap-frozen tissue using Trizol reagent (Ambion, 
Foster City, CA, USA) following the manufacturers 
protocol. Following DNase I treatment using the 
DNA-free™Kit (Ambion, Foster City, CA, USA), total 
RNA concentration and purity were measured using 
Nanodrop spectrophotometer ND-1000 (Thermo 
Scientific, MA, USA). 500 ng RNA was reverse 
transcribed into cDNA using Revert-aid first strand 
cDNA synthesis kit (Thermo Fisher Scientific, Boston, 
MA, USA) using random primers following the 
suggested protocol.  
All Quantitative-PCR experiments except for 
ULBP2 were performed using SYBR Green technology 
(Applied Biosystems, CA, USA). Custom designed 
Taqman primers & probes were used for 
quantification of ULBP2 in frozen tissues 
(Hs00607609_mH). GAPDH and ACTB were used as 
reference genes (4352934E, 4352935E) [8] [9]. Primers 
used for SYBR Green experiments are given in Table 
S3. Q-PCR was performed in a ABI 7500 Real Time 
PCR System (Applied Biosystems, Carlsbad, CA, 
USA) using either Taqman universal master mix 
(Applied Biosystems, Carlsbad, CA, USA) or Power 
SYBR Green master mix (Applied Biosystems, 
Carlsbad, CA, USA), according to manufacturer`s 
protocols. Thermal conditions were 50°C for 2 min for 
UNG enzyme activity, an initial denaturation stage of 
95°C for 10 min., followed by 45 cycles of 95°C 15 sec. 
denaturation, 60°C 1 min. of annealing and extension. 
Data was analyzed using ABI 7500 Software v2.0.4 
and gene expression normalized to two control genes 
GAPDH, ACTB for Taqman experiments and three 
control genes GAPDH, ACTB, 18S for SYBR Green. 
All experiments were repeated at least 3 times for 
each reaction. Gene expression was quantified using 
the 2-ΔΔCT method [10].  
Statistical methods 
Statistical analyses were performed using Graph 
Pad Prism 6 (GraphPad Prism 6 Software, San Diego, 
CA, USA) or SPSS Statistics v.19 (IBM, 2010, Chicago, 
IL, USA). P values below 0.05 were considered 
statistically significant. ANOVA tests were used to 
determine differences among multiple groups when 
comparing gene expression, or cytotoxicity. 
Kaplan-Meier plots and the log-rank test were utilized 
to determine significance in survival differences 
among prognostic groups. Univariate and 
multivariate cox proportional hazards regression 
analysis was performed using SPSS Statistics v.19. 
Results 
Identifying prognostic biomarkers for colon 
cancer with cancer-specific (CSS) or overall 
survival (OS) as end-point measures 
We generated an R based tool (semi-supervised 
survival analysis tool: SSAT) to discover genes whose 
expression correlated with survival (see Methods). 
SSAT analysis of two colon cancer datasets, GSE17536 
and GSE17527, revealed 400 and 269 genes 
respectively, which could generate a statistically 
significant stratification using at least at one of the 7 
SSAT defined thresholds. Among these, 64 probesets 
were common to both datasets, had HRs in the same 
direction and shared the same threshold value for 
both cohorts and therefore were studied further. 
Probesets were ranked from the most to the least 
significant and 20 with the lowest weighted ranksum 
values were included in a multivariate model (MVA) 
that included stage as a confounding factor using 
GSE17536 cancer-specific survival data (Table S4). 
The MVA identified 3 probesets/genes as 
independent prognostic biomarkers of cancer-specific 
survival (Table S5). The same analysis was then 
performed using these 3 probesets and stage for 




GSE17537; which revealed that other than stage, 
ULBP2 and SEMA5A were independent prognostic 
biomarkers for colon cancer when all stages were 
included in the analysis (Figure S2, Figure S3 and 
Table S5) as well as when only stage 2 and 3 patients 
were evaluated (Figure S4). ULBP2 and SEMA5A 
gene expression were also found to be linearly 
associated with cancer specific survival (Table S6). To 
generate a combined gene signature for prognosis 
prediction we used SSAT identified cut-off values and 
classified SEMA5A-high and ULBP2-low patients as 
those with good prognosis (G), while the reverse 
predicted bad (B), and the rest, patients with 
intermediary (I) prognosis. This “SU-GIB” 
stratification was a highly significant prognostic 
classifier for both cohorts (Figure 1), independent of 
confounding factors (Table 1). To validate these 
findings ex vivo we used tumor tissue from a third 
cohort of patients with colon cancer for which overall 
survival time was available as an end-point measure 
(Table S1). The median expression value for SEMA5A 
and ULBP2 mRNA levels, as determined by Q-PCR 
was used to stratify these patients into good and bad 
prognosis groups. Similar to our in silico findings, this 
identified distinct prognostic groups when all stages 
were included in the analysis (Figure S5), as well as 
for patients with stage 2 and 3 disease (Figure S6); 
and the SU-GIB stratification revealed significantly 
distinct prognostic subgroups when qPCR data was 
used (Figure 1). Finally, a MVA that included grade, 
stage, age, gender and the SU-GIB classification 
showed that the SEMA5A/ULBP2 based stratification 
could predict prognosis independent of confounding 
factors (Table 1). The stage independence of SU-GIB 
classification is preserved when only stage II&III 
patients were included into analysis (Table S7).  
As DNA mismatch repair (MMR) status of colon 
cancer can be a prognostic factor, we asked if SU-GIB 
would further stratify patients with and without 
microsatellite instability (MSI). For this purpose we 
predicted the MSI status of samples within the 
GSE17536 dataset and performed SU-GIB 
stratification for both MSI and MSS samples. This 
revealed a significant difference between prognostic 
groups in MSS patients. Although the trend was in the 
expected direction for the MSI group, log-rank test 
did not show a significance, probably due to a low 
sample size (Figure S7). In summary, our results 
suggest that SU-GIB stratification can predict sub 
groups of patients with differing prognosis, 
independent of confounding factors.  
SU-GIB and disease-free survival (DFS) 
SU-GIB stratification identified 3 significantly 
distinct prognostic groups when DFS was used as an 
end-point measure in both GSE17536 and GSE17537 
datasets (Figure S8). When MSI and MSS stable 
groups were analyzed separately a significant 
stratification for patients especially with MSS tumors 
could be seen (Figure 2). This was significant for stage 
2 patients, but was also evident (albeit not significant) 
for stage 3 patients (Figure 3). As the GSE39582 
dataset contains KRAS and BRAF mutation data, we 
included this information in a MVA that included 
additionally SU-GIB and stage. In this model, 
mutational status was not an independent prognostic 




Figure 1. SEMA5A/ULBP2 (SU) gene signature for colon cancer prognostication. Kaplan-Meier graphs based on the SU signature for GSE17536 (A), 
GSE17537 (B) and the Ankara cohort (C), and their respective log-rank p values are shown. Survival times are in months. A combined score based on ULBP2 and 
SEMA5A expression that separates patients into good (SEMA5A high, ULBP low), bad (SEMA5A low, ULBP high) and intermediate (patients with both SEMA5A and 
ULBP2 high or both low) groups results in better stratification of colon cancer patients. ULBP2 and SEMA5A cut-off values were 4 and 6, respectively for in silico 
analyses. For the Ankara cohort, cut-off values correspond to the median expression value for both genes. 




Table 1. Multivariate analysis of clinicopathological parameters and SU-GIB 
GSE17536 - CSS Hazard Ratio 95%CI P* 
Grade** 1.165 0.685 - 1.979 0.573 
Stage† 5.028 3.133 - 8.068 <0.001 
Age (above 65 vs equal to or below 65) 0.818 0.455 - 1.467 0.500 
Gender (female vs. male) 1.018 0.567 - 1.831 0.951 
MSI_transcription based (stable vs. instable) 1.319 0.558 - 3.119 0.529 
SU-GIB# 2.452 1.616 - 3.720 <0.001 
    
GSE17537 - CSS Hazard ratio 95% CI P* 
Stage† 13.662 2.769 - 67.400 0.001 
Age (equal to or below 65 vs. above 65) 1.370 0.292 - 6.434 0.690 
Gender (female vs. male) 0.924 0.183 - 4.668 0.924 
SU-GIB# 4.502 1.557 - 13.017 0.005 
    
Ankara Cohort - OS Hazard ratio 95% CI P* 
Grade** 1.171 0.409 - 3.358 0.769 
Stage‡ 4.481 1.597 - 12.574 0.004 
Age (above 65 vs equal to or below 65) 2.300 0.857 - 6.174 0.098 
Gender (female vs. Male) 1.062 0.407 - 2.775 0.902 
SU-GIB# 3.481 1.514 - 8.004 0.003 
*Cox proportional hazards regression 
**Grade: Treated as a continuous variable; Poorly differentiated (1), moderately differentiated (2), well differentiated (3) 
†Stage: Treated as a continuous variable (1, 2, 3, 4) 
‡Stage: Treated as a continuous variable (1: stage 1, 2: stage 3A and 3B, 3: stage 3C and 4:stage 4) 
# SU-GIB: Treated as a continuous variable (1:Good, 2:Intermediate, 3:Bad) 
 
 
Figure 2. SU-GIB can predict recurrence-free survival especially for microsatellite stable patients in GSE39582. Kaplan-Meier graphs of 
microsatellite instable (MSI, A) and stable (MSS, B) patients stratified independently using SU-GIB, and log-rank p values are shown. Cut-off values for both genes were 
the most significant within the 25th and 75th interquartile range.  
 
SU-GIB prediction compared to other 
molecular classifiers 
Among several prognostic molecular classifiers 
for colon cancer, Oncotype DX colon cancer 
(Oncotype) developed to predict recurrence [6], is one 
that can be applied to microarray expression data [3]. 
We, therefore, tested how the SU-GIB classification 
would compare to the Oncotype score for colon 
cancer patients with stage II or III disease. A MVA 
that included age, gender, stage, tumor grade, MSI 
status and the prognostic tests revealed that both 
SU-GIB or Oncotype were independent prognostic 
classifiers for DFS in cohorts GSE17536 and GSE39582 
(Table S9). When SU-GIB and Oncotype were both 
included in the MVA for GSE39582, SU-GIB was still 
an independent significant prognostic parameter 
when Oncotype was not, suggesting that the two tests 
identify mostly overlapping prognostic sub-groups 
(Table S10). We also asked if the SU-GIB classifier 
could stratify colon cancer patient groups as 
identified by Marisa et al., which is a functional 




classification with 6 molecularly distinct subtypes 
(C1-6). We find that SU-GIB can distinguish 3 groups 
within all categories. However, C1 (DMMR) and C5 
(CINwntup) contained the largest number for G 
tumors, whereas the CSC group (C2) contained the 
largest number of B samples.  
Overall, we find that the SU-GIB classification is 
as powerful as Oncotype in predicting patients with 
recurrence and could be useful even for colon cancer 
subtypes sub-grouped based on given gene 
expression signatures.  
Molecular characteristics of G, I and B tumors 
The Cancer Genome Atlas (TCGA) database 
contains protein as well as RNA based expression 
data for tumors. We, therefore, asked if the SU 
defined prognostic groups differed in terms of 
signaling pathways as could be determined by an 
analysis of the TCGA reverse-phase protein 
expression data (RPPA). When tumors corresponding 
to SU-G, I and B groups were compared, we found 
that “G” tumors showed significantly increased EGFR 
Y1068, Y992 and Shc Y317 phosphorylation, while 
cleaved (activated) Caspase 7 levels were increased in 
“B” tumors (Figure 4 and S9). As Caspase 7 activation 
promotes NFkB target activation [11], we asked if 
inflammatory cytokines were transcriptionally 
upregulated in such tumors. Indeed, several 
inflammatory cytokines, including IL6, IL1β, TGFβ1, 
TGFβ3, IL1R2, and TNFα were upregulated among B 
tumors (Figure 5 and S10). Inflammation has been 
associated with epithelial-to-mesenchymal transition 
(EMT) in several tumors including colon cancer [12]. 
When tumors with G, I and B genotypes as 
determined for the GSE36582 dataset were analyzed 
for Vimentin and E-cadherin expression 
(mesenchymal and epithelial markers, respectively), 
we observed that the majority of “G” tumors are 
epithelial in nature while “B” tumors are mostly 
mesenchymal when “I” tumors show an intermediary 
phenotype (Figure S11). We, therefore, conclude that 
the SU-GIB classification identifies tumor subgroups 
that differ in terms of EGFR signaling, inflammation 
and EMT-related characteristics.  
 
 
Figure 3: SU-GIB can predict recurrence-free survival for micosatellite stable patients with stage 2 or 3 disease in GSE39582. Kaplan-Meier graphs 
and log-rank p values are shown for stage 2 (A, B) and 3 (C, D) patients with microsatellite instable (A, C) and stable (B, D) tumors. Cut-off values for both genes were 
the most significant within the 25th and 75th interquartile range. 





Figure 4. TCGA based proteome analysis of colon cancer tumor tissue reveals increased EGFR phosphorylation and decreased Caspase 7 
cleavage in the good prognosis group. RNA seq. and proteome data for 132 colon cancer primary tumor tissues downloaded from “cancergenome.nih.gov” via 
the TCGA data portal classified according to the SU signature (bad survivors: 40, good survivors: 37, intermediate survivors: 55) revealed increased EGFR 1068 
phosphorylation among patients with better prognosis (p<0.001, 1-way Anova) (left). The same analysis showed increased Caspase 7 cleavage in patients within the 
worse survival group (p<0.0001) (right). Caspase 7 cleavage was directly correlated with ULBP2 and inversely with SEMA5A expression (p<0.001 for both genes by 
Pearson’s r). The mean and standard deviation for each group are indicated. 
 
Figure 5. TCGA based RNA seq. analysis of colon cancer tumor tissue reveals increased inflammatory cytokine gene expression in the bad 
prognosis group. TCGA colon tumor samples were stratified into GIB groups using median expression values as cut-offs for ULBP2 and SEMA5A. RPKM values of 
IL6, IL1B, TGFB1 are plotted for “good”, “intermediate” and “bad” groups. T-test p values between “good” and “bad” groups. *p < 0.05, **p <0.01, ***p <0.0001. 
RPKM: reads per kilobase per million mapped reads. The median and inter-quartile ranges for each group are indicated. 
 
SU-GIB as a potential predictor of drug 
responsiveness 
As prognostic classifiers are especially valuable 
if they can also predict response to therapy we aimed 
to identify drugs that would be suitable for the 
treatment of especially the bad prognosis group as 
identified by SU-GIB. For this purpose, we correlated 
IC50 values of all drugs tested for colon cancer cell 
lines in the CGP database [5] with SEMA5A and 
ULBP2 expression, and identified 13 drugs whose 
IC50 values showed significant direct and inverse 
correlations with SEMA5A and ULBP2 expression, 
respectively (Table S11). Among these drugs, the 
most significant correlation with both genes in the 
expected direction was for the PI3K/mTOR inhibitor 
NVP-BEZ235 (Figure 6), suggesting that the SU-GIB 
stratification can possibly be utilized as a companion 
diagnostic test of sensitivity for a variety of drugs. 
 





Figure 6. Chemosensitivity profiles of colon cancer cell lines 
corresponding to SU-G, -I and -B phenotypes. In silico analysis of colon 
cancer cell lines as classified by the SU signature into G, I or B phenotypes for 
NVP-BEZ235 cytotoxicity based on CGP data. Cut-off values used to generate 
a SU-GIB stratification were either the SSAT generated (SEMA5A) or the 
median expression values (ULBP2).  
 
Discussion 
Despite the availability of a large number of 
molecular tests capable of determining prognosis of 
colon cancer patients, very few have progressed 
beyond diagnostic and initial validation studies. An 
extensive report by the US Department of Health and 
Human Services which reviewed prognostic tests for 
cancer highlighted critical aspects that would have to 
be considered in the design of future discovery and 
validation studies, to help speed their introduction 
into routine clinical practice [1]. As the report 
emphasized the use of different patient cohorts, we 
designed this study to include multiple cohorts for 
both in silico, as well as ex vivo validation. The same 
report stresses the importance of performing MVAs 
that not only include all confounding factors but also 
utilize OS and/or CSS as end measures, in addition to 
DFS. We therefore utilized OS/CSS in our discovery 
method, subsequently validating our gene signature 
for DFS as well. Our results suggest that the SU-GIB 
stratification can be developed as a clinical prognostic 
test for colon cancer, especially since the strength of 
the test is comparable to that of an in silico adapted 
version of Oncotype DX colon. Obviously extensive 
validation studies are required to define the best 
patient group that would benefit from the SU-GIB 
test, as has been done previously for others [13, 14]. 
This would need to be followed by studies that would 
assess if treatment decisions can be altered by the 
SU-GIB test, which is considered a major criterion for 
clinical usability [15]. The in silico predictions for MSI 
status and Oncotype scores performed in this study 
are approximations at best, and actual test results of 
these would need to be included in validation studies.  
To our knowledge, this is the first report to 
associate SEMA5A and ULBP2 expression with 
clinical outcome in colon cancer. Semaphorins were 
first identified as axon guidance molecules involved 
in regulation of neural connections [16]. Type 5 
semaphorins are transmembrane proteins present in 
both invertebrates and vertebrates[17]. In cancer, their 
upregulation has been related to both good and bad 
prognosis [18]. For example Sema5a transfection to 
pancreatic cancer cell lines resulted in higher cell 
invasion in vitro, and injection of such cells to nude 
mice enhanced tumorgenicity and tumor growth in 
vivo [19]. Similarly, SEMA5A has been shown to 
promote in vitro migration and invasion of gastric 
cancer cell lines [20]. On the other hand, SEMA5A has 
been reported to impede glioma cell motility [21], and 
has been associated with better prognosis in women 
with non-small cell lung cancer [22]. According to the 
Human Protein Atlas, SEMA5A expression occurs 
mostly in epithelial cells (www.proteinatlas.org), 
possibly indicating that this is an epithelial cell 
marker for colon cancer. On the other hand, analysis 
of ULBP2 expression in the same database reveals that 
it occurs more often in fibroblasts, compared to 
surrounding cells in various organs, and therefore in 
cells that are more mesenchymal in nature. ULBP2, a 
NKG2D ligand, is highly expressed in transformed 
cells [23] and is thought to provide a ligand for NK 
cells, facilitating tumor cell death [24-26]. The reason 
up-regulation of ULBP2 is related to a worse outcome 
could be because secretion or cleavage of this protein 
is related to reduced NK mediated tumor lysis [27]. In 
this line, an increase in expression of the 
tumor-associated or the secreted form of ULBP2 has 
been associated with an unfavorable outcome for 
several cancers including melanoma, non-small cell 
lung carcinoma and ovarian carcinoma [28-30]. 
Hence, the known molecular characteristics of these 
two genes help understand how they might affect 
prognosis in colon cancer. Our findings show that 
patients with a better outcome have increased 
phosphorylation of EGFR at Tyrosine 1068. The 
autophosphorylation of this residue is necessary for 
Grb2-EGFR binding and is strongly inhibited by 
Gefinitib [31, 32]. It is somewhat surprising then, that 
a PI3K/mTOR inhibitor is effective preferentially on 
tumors from patients with a worse prognosis, when 
both PI3K and mTOR are activated downstream to 
EGFR. However, our analysis of the GSE39582 
database, which contains mutation data, shows that 
tumors from only 20% of SU-G patients contain Kras 
or Braf mutations, while tumors from B patients are 
mutated at a rate of 60%. This suggests that most 
patients with EGFR Tyr 1068 phosphorylation might 




not harbor Kras/Braf mutations; and that the 
PI3K-mTOR inhibitor BEZ235 might be more effective 
on tumors with Kras/Braf mutations, rather than 
those with EGFR autophosphorylation. Several 
reports indicate an inverse association of 
EGFR/Kras/MAPK and PI3K activity and caspase 7 
activation by its cleavage [33, 34], similar to our 
findings. Caspase 7 activation is involved in 
inflammation [35] and enhances NFkB activity [11]. It 
is therefore, not surprising that we find several 
inflammatory cytokines upregulated among SU-B 
tumors. Inflammation, in turn, is closely associated 
with epithelial to mesenchymal transition [36]. Our 
results show that SU-B tumors are significantly more 
mesenchymal in their phenotype compared to SU-G 
tumors, as assessed by Vimentin and E-cadherin 
expression, two genes which are considered reliable 
markers of mesenchymal and epithelial cells, 
respectively [37]. In summary, our data shows that the 
SU-GIB stratification not only defines distinct 
prognostic sub-groups but also functionally distinct 
colon cancer sub-types. Further validation of this 
signature, especially in prospectively studied cohorts, 
and further characterization of SU-GIB stratified 
tumors could reveal various novel options for 
treatment and diagnosis of colon cancer.  
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